Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denali Deal & F-star’s Innovative Asset Centric Business Model

Executive Summary

Jane Dancer, chief business officer at F-star – a Cambridge, UK-based biotech – chats to Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe partnering conference in Cologne, Germany.

Advertisement

Related Content

F-star Option Deal With Merck On Bispecific IO Antibodies
Up Front Or Back End? Considering The Best Structure For Milestone Fees
Video Interview: F-star CEO Details Asset-Centric Ambitions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel